Search
01/01/2022
Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up
Santos García D, Canfield H, de Deus Fonticoba T, Cores Bartolomé C, Naya Ríos L, García Roca L, Martínez Miró C, Jesús S, Aguilar M, Pastor P, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Puente V, Dotor J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Blázquez Estrada M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues O, González Ardura J, Alonso Redondo R, Ordás C, López Díaz LM, McAfee D, Martinez-Martin P, Mir P, COPPADIS Study Group. Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinsons Disease. 2022; 12(3)DOI:10.3233/JPD-213004. PMID:34957949. IF:5.200(Q1/3D).
01/01/2022
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease
Sampedro, F, Martinez-Horta, S, Marin-Lahoz, J, Pagonabarraga, J, Kulisevsky, J. Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease. Journal of Parkinsons Disease. 2022; 12(5)DOI:10.3233/JPD-223223. PMID:35491803. IF:5.200(Q1/3D).
01/01/2022
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (vol 11, pg 187, 2021)
Abbruzzese, G, Kulisevsky, J, Bergmans, B, Gomez-Esteban, JC, Kagi, G, Raw, J, Stefani, A, Warnecke, T, Jost, WH. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (vol 11, pg 187, 2021). Journal of Parkinsons Disease. 2022; 12(1)DOI:10.3233/JPD-219007. PMID:34275911. IF:5.200(Q1/3D).
01/01/2022
Functional changes in prefrontal cortex following frequency-specific training
Bach-Morrow L., Boccalatte F., DeRosa A., Devos D., Garcia-Sanchez C., Inglese M., Droby A.. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4.600(Q2/4D).
01/01/2022
Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins
Pou M.A., Orfila F., Pagonabarraga J., Ferrer-Moret S., Corominas H., Diaz-Torne C.. Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins. Revue Du Rhumatisme (edition Francaise). 2022; 89(6)DOI:10.1016/j.rhum.2022.09.019. PMID:. IF:(Q/D).
01/01/2022
Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert
Kulisevsky J.. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. REVISTA DE NEUROLOGIA. 2022; 75(s04)DOI:10.33588/rn.75s04.2022217. PMID:36342310. IF:1.200(Q4/10D).
01/01/2022
Efficacy and safety of high doses of safinamide in advanced Parkinson disease
Rodríguez-Jorge F., Beltrán-Corbellini Á., Chico-García J.L., Parra-Díaz P., Baena-Álvarez B., Pagonabarraga J., Pérez-Torre P., Pareés I., López-Sendón J.L., Martínez-Castrillo J.C., Alonso-Cánovas A.. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. PARKINSONISM & RELATED DISORDERS. 2022; 97DOI:10.1016/j.parkreldis.2022.03.010. PMID:35344893. IF:(Q/D).
01/01/2022
The Beneficial Effects of Heme Oxygenase 1 and Hydrogen Sulfide Activation in the Management of Neuropathic Pain, Anxiety- and Depressive-like Effects of Paclitaxel in Mice
Roch, G, Batalle, G, Bai, X, Pouso-Vazquez, E, Rodriguez, L, Pol, O. The Beneficial Effects of Heme Oxygenase 1 and Hydrogen Sulfide Activation in the Management of Neuropathic Pain, Anxiety- and Depressive-like Effects of Paclitaxel in Mice. Antioxidants. 2022; 11(1)DOI:10.3390/antiox11010122. PMID:35052626. IF:7.000(Q1/1D).